Table 2.
Comparisons of coagulation measures between 32 patients – 15 with CRAO, 17 with AF, and 104 healthy, normal controls
| Coagulation measures (normal range) | Abnormal in CRAO | Abnormal in controls | P | OR, 95% CI |
|---|---|---|---|---|
| Homocysteine (≤13.5 μmol/L) | 22% (7/32) | 2% (2/102) | Fisher’s P = 0.0006 | 14.0, 2.7–71.6 |
| Lupus anticoagulant | 28% (7/25) | 9% (7/81) | Fisher’s P = 0.02 | 4.1, 1.3–13.2 |
| Factor V Leiden mutation | 6% CT (2/32) | 2% CT (2/104) | Fisher’s P = 0.2 | |
| Resistance to activated protein C (dated cutpoint) | 7% (2/30) | 5% (5/92) | Fisher’s P = 1.0 | |
| Prothrombin gene mutation | 6% CT (2/32) | 3% CT (3/105) | Fisher’s P = 0.3 | |
| Plasminogen activator inhibitor gene mutation | 29% 4G4G (9/31) | 26% 4G4G (26/100) | Mantel-Haenszel | |
| 52% 4G5G (16/31) | 43% 4G5G (43/100) | χ2 = 0.92, P = 0.3 | ||
| MTHFR C677T mutation | 42% CC (13/31) | 31% CC (31/101) | Mantel-Haenszel | |
| 19% CT (6/31) | 14% CT (14/101) | χ2 = 2.26, P = 0.1 | ||
| Antigenic protein C (≥73%) | 13% (4/32) | 7% (6/92) | Fisher’s P = 0.3 | |
| Antigenic protein S (≥63%) | 0% (0/32) | 4% (4/92) | Fisher’s P = 0.6 | |
| Antigenic-free protein S (≥66%) | 3% (1/30) | 2% (2/92) | Fisher’s P = 1.0 | |
| Antithrombin III (≥80) | 10% (3/31) | 2% (2/92) | Fisher’s P = 0.1 | |
| Anticardiolipin antibody IgG (<22 GPL) | 9% (3/32) | 7% (7/104) | Fisher’s P = 0.7 | |
| Anticardiolipin antibody IgM (<10 MPL) | 6% (2/32) | 2% (2/104) | Fisher’s P = 0.2 | |
| Plasminogen activator inhibitor (≤21.1 U/mL) | 13% (4/30) | 10% (10/97) | Fisher’s P = 0.7 | |
| Lp(a) (<35 mg/dL) | 13% (4/31) | 20% (20/102) | χ2 = 0.72, P = 0.4 | |
| Factor VIII (<150%) | 19% (6/32) | 7% (7/98) | Fisher’s P = 0.1 | |
| Factor XI (<150%) | 9% (3/32) | 2% (2/96) | Fisher’s P = 0.1 |
Abbreviations: CI, confidence interval; C, mutant allele; OR, odds ratio; T, wild-type normal allele; Lp(a), lipoprotein a; CRVO, central retinal vein occlusion; Ig, immunoglobulin.